fmcg unilever?, page-10

It appears also that Hammond has some history with Unilever (among others)

http://www.obj.com.au/wp-content/uploads/OBJ-Technology-and-Introduction-Booklet.pdf
Dr Kevin Hammond - International Partnering Manager -
Dr Hammond has over 30 years experience with leading pharmaceutical, FMCG and Cosmetic companies where he held responsiblities in directing partnering, licensing and new product innovations for companies such as Reckitt Benckiser, Unilever, PZ Cussons, CB Fleet (US) and GSK. Dr Hammond is a visiting lecturer at London College and a member of the Editorial Board of the International Journal of Cosmetic Science. Dr Hammond is based in the
UK and manages OBJ?s European base for partnering, evaluation and product development activities.

I think that surges, abdm et al have already had the discussion about a potential Reckitt Benchiser connection on another thread last year.

Having a quick look at their website in terms of product suitability for FIM, eM-Patch or Dermaportation technologies here's some more speculation around potential product lines that might be amenable to our technology.

(Curiously the major product categories of RB are similar to those referred to regularly on OBJ's website)

http://www.rb.com/Investors-media/Category-performance
(% is the % net revenue to RB)

Fabric care 22% (Vanish or Spray'n'Wash stain removal)
Surface Care 17% (Dettol and Lysol antibacterials)
Dishwashing 11% (probably none)
Home Care 14% (Airwick, Mortein and potentially shoe care)
Health and Personal care 26% (Nurofen - given that ibuprofen has already been demonstrated by OBJ in transdermal delivery - as well as Veet, Clearasil and Dettol)
Food 3% (probably none)
Pharmaceutical (Suboxone - for the treatment of opioid dependence and dermaportation potential)

bluebush